Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA) is scheduled to be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Price Performance

Shares of HUMA traded down $0.03 during trading hours on Thursday, reaching $5.40. 267,453 shares of the company traded hands, compared to its average volume of 2,335,853. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $644.49 million, a PE ratio of -4.31 and a beta of 1.47. Humacyte has a fifty-two week low of $2.08 and a fifty-two week high of $9.97. The stock has a fifty day simple moving average of $5.49 and a 200 day simple moving average of $6.12.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. Insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HUMA. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Benchmark reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. Piper Sandler set a $6.00 price objective on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $11.00.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.